Interpace Biosciences (OTCMKTS:IDXG) Announces Quarterly Earnings Results

Interpace Biosciences (OTCMKTS:IDXG) issued its quarterly earnings data on Tuesday. The business services provider reported $0.03 earnings per share (EPS) for the quarter, Zacks reports. Interpace Biosciences had a return on equity of 493.02% and a net margin of 63.46%.

Interpace Biosciences Trading Down 3.4%

Shares of OTCMKTS IDXG traded down $0.07 during trading on Tuesday, reaching $2.00. The company had a trading volume of 158 shares, compared to its average volume of 8,454. Interpace Biosciences has a twelve month low of $0.70 and a twelve month high of $2.40. The stock has a market capitalization of $8.86 million, a PE ratio of -100.00 and a beta of 0.65. The stock has a 50-day moving average price of $1.90 and a two-hundred day moving average price of $1.52.

Interpace Biosciences Company Profile

Interpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.